CAS 1629229-37-3 appears in our catalog under these names: Fezolinetant/ 99.7% (existing batch purity), Fezolinetant (ESN–364), Fezolinetant, Fezolinetant 98%, [(8R)-5,6-Dihydro-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl](4-fluorophenyl)methanone, 98%, 98%. Offered by: TargetMol, GLPBio, Biosynth, Ambeed, Chemat. Available pack sizes: 1mg, 5mg, 10mg, 25mg, 50mg, 100mg, 10mM (in 1ml dmso), 250mg.
Fezolinetant is a triazolopyrazine that is 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine substituted by 3-methyl-1,2,4-thiadiazol-5-yl, 4-fluorobenzoyl and methyl groups at positions 3, 7, and 8R, respectively. It is a prescription medicine used to reduce moderate to severe vasomotor symptoms due to menopause. It has a role as a neurokinin-3 receptor antagonist. It is a tertiary carboxamide, a member of benzamides, a member of thiadiazoles, a triazolopyrazine and a member of monofluorobenzenes.
Source: ChEBI
| Molecular formula | C16H15FN6OS |
|---|---|
| Molecular weight | 358.4 g/mol |
| IUPAC name | (4-fluorophenyl)-[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone |
| InChIKey | PPSNFPASKFYPMN-SECBINFHSA-N |
| SMILES | C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C |
Computed by PubChem (NCBI)